Swiss pharmaceutical company Novartis announced Tuesday that it had discontinued the development of two drugs — the hepatitis C treatment Zalbin, and antifungal agent Mycograb. The company will take impairment charges of appro…
Federal investigators are looking into allegations that major drug companies, including Merck, AstraZeneca, Bristol-Myers Squibb and GlaxoSmithKline, paid bribes overseas to boost sales and accelerate approvals.
…
Endo Pharmaceuticals (ENDP) agreed to buy generics company Qualitest Pharmaceuticals for $1.2 billion cash.
Qualitest is the sixth-largest U.S. generics company as measured by prescriptions filled. Qualitest will add about $400 million to Endo’s annual revenue and 40 cents per share in annual adjusted earnings, Endo said in a statement.
“We believe that this transaction will…
Continue reading Endo to Acquire Generics Company Qualitest for $1.2 Billion
Endo to Acquire Generics Company Qualitest for $1.2 Billion originally appeared on DailyFinance on Tue, 28 Sep 2010 06:31:00.
Filed Under: Company News, Health Care, Retail
Novartis (NVS) agreed to sell the U.S. rights to bladder medicine Enablex for $400 million.
Ireland-based Warner Chilcott will take over the marketing, sales and manufacturing of the drug in the United States, Novartis said in a statement. The deal is expected to close by the end of October.
Novartis may also receive “milestone payments” of as much as $20 million.
In 2005, Novartis…
Continue reading Novartis Sells U.S. Rights to Enablex for $400 Million
Novartis Sells U.S. Rights to Enablex for $400 Million originally appeared on DailyFinance on Fri, 24 Sep 2010 06:46:00.
Filed Under: Company News, Health Care, Novartis, Insurance, Retail
While a new report from Goldman Sachs says health care is in a state of flux that most of the sector’s companies haven’t adjusted to yet, it also pinpoints four that have plenty of cash that could be put to good use for investo…